Quale sarebbe il prezzo per Artiva Biotherapeutics, Inc. (ARTV)

Il prezzo per Artiva Biotherapeutics, Inc. (ARTV) è $11.09

Qual è la capitalizzazione di mercato per Artiva Biotherapeutics, Inc. (ARTV)

La capitalizzazione di mercato per Artiva Biotherapeutics, Inc. (ARTV) è $542.19M

Artiva Biotherapeutics, Inc. (ARTV) Rendimento del Dividendo

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Anno	Rendimento da dividendi	Cambia
Non abbastanza dati per le date fornite.

Anno

Rendimento da dividendi

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rendimento da dividendi	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

Azienda

Rendimento da dividendi

Il paese